Emergence of crenolanib for FLT3-mutant AML

Blood

Volumn 122, Issue 22, 2013, Pages 3547-3548

  Fathi, Amir T ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRENOLANIB; FLT3 LIGAND; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; QUIZARTINIB; RAS PROTEIN; SORAFENIB; STAT5 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CANCER GROWTH; CELL DIFFERENTIATION; DRUG EFFICACY; HUMAN; LEUKEMIA CELL; LEUKEMIA RELAPSE; PHASE 2 CLINICAL TRIAL (TOPIC); POINT MUTATION; PRIORITY JOURNAL; REVIEW;

EID: 84888260780     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-10-528992     Document Type: Review

References (10)

1. Zimmerman EI, Turner DC, Buaboonnam J, et al. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Blood. 2013;122(22):3607-3615.
2. Fathi AT, Chabner BA. FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations. Oncologist. 2011;16(8):1162-1174.
3. Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10(12):1911-1918.
4. Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, Reilly JT. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol. 2001;113(4):983-988.
5. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99(12):4326- 4335.
6. Gale RE, Green C, Allen C, et al; Medical Research Council Adult Leukaemia Working Party. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111(5):2776-2784.
7. Mizuki M, Fenski R, Halfter H, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood. 2000;96(12):3907-3914.
8. von Bubnoff N, Engh RA, Aberg E, Sänger J, Peschel C, Duyster J. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res. 2009;69(7):3032-3041.
9. Galanis A, Rajkhowa T, Muralidhara C, Ramachandran A, Levis M. Crenolanib is a highly potent, selective, FLT3 TKI with activity against D835 mutations [abstract]. Blood. 2012;120. Abstract 1341.
10. Smith CC, Lasater E, McCreery M, et al. Crenolanib (CP-868, 596) is a potent and selective type I FLT3 inhibitor that retains activity against AC220 resistancecausing FLT3 kinase domain mutations [abstract]. Blood. 2012;120. Abstract 141.